AlzeCure Pharma Future Growth
Future criteria checks 2/6
AlzeCure Pharma is forecast to grow earnings and revenue by 61.2% and 178.1% per annum respectively while EPS is expected to decline by 51.4% per annum.
Key information
61.2%
Earnings growth rate
-51.4%
EPS growth rate
Pharmaceuticals earnings growth | 20.6% |
Revenue growth rate | 178.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 26 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 0 | -7 | -65 | -65 | 1 |
12/31/2024 | N/A | -46 | 17 | 17 | 1 |
3/31/2024 | N/A | -37 | -35 | -35 | N/A |
12/31/2023 | N/A | -37 | 3 | 3 | N/A |
9/30/2023 | N/A | -38 | -40 | -40 | N/A |
6/30/2023 | N/A | -42 | -47 | -47 | N/A |
3/31/2023 | N/A | -53 | -14 | -14 | N/A |
12/31/2022 | N/A | -56 | -100 | -100 | N/A |
9/30/2022 | N/A | -68 | -70 | -70 | N/A |
6/30/2022 | N/A | -73 | -70 | -70 | N/A |
3/31/2022 | N/A | -67 | -110 | -110 | N/A |
12/31/2021 | N/A | -78 | -71 | -71 | N/A |
9/30/2021 | N/A | -73 | -70 | -70 | N/A |
6/30/2021 | N/A | -78 | -75 | -75 | N/A |
3/31/2021 | N/A | -81 | -78 | -78 | N/A |
12/31/2020 | N/A | -71 | -70 | -70 | N/A |
9/30/2020 | N/A | -69 | -64 | -63 | N/A |
6/30/2020 | N/A | -61 | -57 | -56 | N/A |
3/31/2020 | N/A | -53 | -50 | -49 | N/A |
12/31/2019 | N/A | -51 | -52 | -50 | N/A |
9/30/2019 | N/A | -48 | -50 | -49 | N/A |
6/30/2019 | -2 | -40 | -44 | -42 | N/A |
3/31/2019 | -1 | -38 | -40 | -39 | N/A |
12/31/2018 | N/A | -36 | -37 | -36 | N/A |
9/30/2018 | 1 | -28 | -30 | -29 | N/A |
12/31/2017 | 1 | -10 | N/A | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AC6 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AC6 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AC6 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AC6's revenue (178.1% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: AC6's revenue (178.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AC6's Return on Equity is forecast to be high in 3 years time